Impact of Dementia-Related Behavioral Symptoms on Healthcare Resource Use and Caregiver Burden: Real-World Data from Europe and the United States.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2021
Historique:
pubmed: 1 6 2021
medline: 21 9 2021
entrez: 31 5 2021
Statut: ppublish

Résumé

Dementia is commonly accompanied by neurobehavioral symptoms; however, the relationship between such symptoms and health-related outcomes is unclear. To investigate the impact of specific neurobehavioral symptoms in dementia on healthcare resource use (HCRU), patient quality of life (QoL), and caregiver burden. Data were taken from the 2015/16 Adelphi Real World Dementia Disease Specific Programme™, a point-in-time survey of physicians and their consulting dementia patients. Multiple regression analyses were used to examine associations between patient symptom groups and health-related outcomes. Each patient symptom group of interest (patients with agitation/aggression and related symptoms [AARS] with psychosis, patients with AARS without psychosis, and patients with other behavioral symptoms) had a positive association with HCRU variables (i.e., HCRU was greater), a negative association with proxy measures of patient QoL (i.e., QoL was decreased), and a positive association with caregiver burden (i.e., burden was greater) compared with patients with no behavioral symptoms (control group). The magnitude of effect was generally greatest in patients with AARS with psychosis. Regression analysis covariates that were found to be most often significantly related to the outcomes were dementia severity and the patients' living situation (i.e., whether they were in nursing homes or living in the community). Combinations of behavioral symptoms, particularly involving AARS plus psychosis, may have a detrimental impact on health-related outcomes such as HCRU, patient QoL, and caregiver burden in dementia. Our results have implications for intervention development in patients who report clusters of symptoms and caregivers, and for identifying at-risk individuals.

Sections du résumé

BACKGROUND
Dementia is commonly accompanied by neurobehavioral symptoms; however, the relationship between such symptoms and health-related outcomes is unclear.
OBJECTIVE
To investigate the impact of specific neurobehavioral symptoms in dementia on healthcare resource use (HCRU), patient quality of life (QoL), and caregiver burden.
METHODS
Data were taken from the 2015/16 Adelphi Real World Dementia Disease Specific Programme™, a point-in-time survey of physicians and their consulting dementia patients. Multiple regression analyses were used to examine associations between patient symptom groups and health-related outcomes.
RESULTS
Each patient symptom group of interest (patients with agitation/aggression and related symptoms [AARS] with psychosis, patients with AARS without psychosis, and patients with other behavioral symptoms) had a positive association with HCRU variables (i.e., HCRU was greater), a negative association with proxy measures of patient QoL (i.e., QoL was decreased), and a positive association with caregiver burden (i.e., burden was greater) compared with patients with no behavioral symptoms (control group). The magnitude of effect was generally greatest in patients with AARS with psychosis. Regression analysis covariates that were found to be most often significantly related to the outcomes were dementia severity and the patients' living situation (i.e., whether they were in nursing homes or living in the community).
CONCLUSION
Combinations of behavioral symptoms, particularly involving AARS plus psychosis, may have a detrimental impact on health-related outcomes such as HCRU, patient QoL, and caregiver burden in dementia. Our results have implications for intervention development in patients who report clusters of symptoms and caregivers, and for identifying at-risk individuals.

Identifiants

pubmed: 34057080
pii: JAD201483
doi: 10.3233/JAD-201483
pmc: PMC8293640
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1567-1578

Références

Int Psychogeriatr. 2012 Oct;24(10):1536-52
pubmed: 22612881
Clin Gerontol. 2018 May-Jun;41(3):249-254
pubmed: 29252121
Am J Psychiatry. 2000 May;157(5):708-14
pubmed: 10784462
Alzheimers Dement. 2011 Sep;7(5):532-9
pubmed: 21889116
Alzheimer Dis Assoc Disord. 2004 Oct-Dec;18(4):223-30
pubmed: 15592135
Int J Geriatr Psychiatry. 2019 Jul;34(7):966-973
pubmed: 30897238
Dement Geriatr Cogn Disord. 2003;15(2):99-105
pubmed: 12566599
Rev Med Interne. 2003 Oct;24 Suppl 3:319s-324s
pubmed: 14710451
Dtsch Arztebl Int. 2017 Jun 30;114(26):447-454
pubmed: 28705297
Dement Geriatr Cogn Disord. 2007;24(3):169-76
pubmed: 17641527
Int Psychogeriatr. 1996;8 Suppl 3:497-500
pubmed: 9154615
Epidemiol Psychiatr Sci. 2018 Jun;27(3):278-287
pubmed: 28065176
Int Psychogeriatr. 2017 Feb;29(2):195-208
pubmed: 27806743
Continuum (Minneap Minn). 2018 Jun;24(3, BEHAVIORAL NEUROLOGY AND PSYCHIATRY):783-803
pubmed: 29851878
J Alzheimers Dis. 2016 Nov 1;55(1):259-267
pubmed: 27662302
Br J Psychiatry. 2009 Mar;194(3):212-9
pubmed: 19252147
Curr Med Res Opin. 2008 Nov;24(11):3063-72
pubmed: 18826746
J Alzheimers Dis. 2018;66(3):1027-1040
pubmed: 30372674
Int J Geriatr Psychiatry. 2004 Mar;19(3):256-65
pubmed: 15027041
BMJ Open. 2016 Aug 16;6(8):e010352
pubmed: 27531722
Curr Alzheimer Res. 2010 Sep;7(6):517-26
pubmed: 20455862
Int J Geriatr Psychiatry. 2014 Jun;29(6):562-8
pubmed: 24677112
Gerontologist. 1980 Dec;20(6):649-55
pubmed: 7203086
Eur Psychiatry. 2005 Nov;20(7):490-6
pubmed: 16310680
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Clin Epidemiol. 2014 Jan 08;6:37-48
pubmed: 24470773
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
BMC Geriatr. 2010 Nov 30;10:87
pubmed: 21118498
Alzheimer Dis Assoc Disord. 2015 Jan-Mar;29(1):50-4
pubmed: 24936799
J Alzheimers Dis. 2018;64(4):1077-1083
pubmed: 30010124

Auteurs

Farid Chekani (F)

Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.

James Pike (J)

Adelphi Real World, Bollington, UK.

Eddie Jones (E)

Adelphi Real World, Bollington, UK.

Joseph Husbands (J)

Adelphi Real World, Bollington, UK.

Rezaul K Khandker (RK)

Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH